Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4978516 | 0.97 | HSP90AB1 (0.46) | HPGDALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4976292 | 0.93 | HPGD (0.48) | HPGDALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4978123 | 0.90 | HSP90AB1 (0.46) | MEN1KMT2AHSP90AB1HRH3KDM2B | |
| SCHEMBL4980394 | 0.89 | KDM2B (0.55) | HPGDMEN1KMT2AHSP90AB1HRH3 | |
| SCHEMBL4980183 | 0.88 | MEN1 (0.49) | MEN1KMT2AHSP90AB1HRH3KDM2B | |
| SCHEMBL4977984 | 0.87 | HSP90AB1 (0.47) | HSP90AB1HRH3POLBKDM2B | |
| SCHEMBL4979058 | 0.86 | KDM2B (0.53) | MEN1KMT2AHSP90AB1HRH3POLB | |
| SCHEMBL4976026 | 0.86 | HRH3 (0.54) | ALDH1A1HSP90AB1HRH3POLBKDM2B | |
| SCHEMBL4976400 | 0.86 | HSP90AB1 (0.47) | ALDH1A1SMN1; SMN2HSP90AB1 | |
| SCHEMBL4976783 | 0.85 | HSP90AB1 (0.49) | HSP90AB1HRH3KDM2BL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | HPGD 159/4885ALDH1A1 1142/4885MEN1 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.